Peak of Standardized Uptake Value in Oral Cancer Predicts Survival Adjusting for Pathological Stage

HIDENORI SUZUKI1, TSUNEO TAMAKI2, MASAMI NISHIO3, SHINTARO BEPPU1, NOBUAKI MUKOYAMA4, NOBUHIRO HANAI1, DAISUKE NISHIKAWA1, YUSUKE KOIDE1 and YASUHISA HASEGAWA1

1Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan; 2Department of East Nagoya Imaging Diagnosis Center, Nagoya, Japan; 3Department of Radiology, Nagoya Positron Emission Tomography Imaging Center, Nagoya, Japan; 4Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Abstract. Background/Aim: To predict survival outcomes of different patients with the same stage of disease is difficult. The possible correlation between 18F-fluorodeoxyglucose (18F-FDG) uptake parameters and survival outcomes was investigated in oral squamous cell carcinoma patients by multivariate analysis adjusted for the pathological stage according to the 8th edition of the tumor-node-metastasis (TNM) classification of the Union for International Cancer Control. Patients and Methods: 18F-FDG-uptake parameters of 28 patients were assessed by positron emission tomography with computed tomography (PET/CT). Results: A peak of standardized uptake value of primary tumor (p-SUVpeak) of ≥14.1 was significantly correlated with shorter overall survival by univariate and multivariate analyses adjusted for the pathological TNM stage. A p-SUVpeak of ≥14.1 was significantly associated with shorter local recurrence-free survival and disease-free survival. Conclusion: A higher p-SUVpeak on pretreatment 18F-FDG-PET/CT is a prognostic parameter of identifying lower survival outcomes.

The tumor-node-metastasis (TNM) staging system is applied worldwide as a predictor of various carcinomas, including oral squamous cell carcinoma (OSCC), but it is difficult to predict survival outcomes of different patients with the same stage (1, 2). Parameters of 18F-2-deoxyglucose (18F-FDG) uptake, as assessed by positron emission tomography with computed tomography (PET/CT), in head and neck cancer, were shown to be associated with overall survival (OS) by multivariate analysis adjusted for TNM stage of the 7th edition of the Union for International Cancer Control (UICC7th) (3, 4). However, no study has yet investigated the association between survival outcomes and 18F-FDG-uptake parameters in OSCC by multivariate analysis adjusted for TNM stage based on the 8th edition of the Union for International Cancer Control (UICC8th) published in 2017 (1).

In OSCC, the presence of pathological lymph node metastasis (pN+) is the most classical predictor, and the presence of extranodal extension (ENE+) is widely accepted as being predictive of poor survival (5, 6). The maximum standardized uptake value (SUVmax), which is commonly used as 18F-FDG-uptake parameter, was reported to predict the risk of both pN+ and ENE+ (7, 8). However, usefulness of volumetric 18F-FDG-uptake parameters, such as metabolic tumor volume (MTV), total lesion glycolysis (TLG), peak of standardized uptake value (SUVpeak), to predict both pN+ and ENE+ remains unknown.

Therefore, the aim of this study was to identify associations between 18F-FDG-uptake parameters and survival outcomes in OSCC by univariate and multivariate analyses adjusted for the pathological TNM stage based on UICC8th, and determine whether 18F-FDG-uptake parameters, including volumetric parameters, are correlated with either pN+ or ENE+.

Patients and Methods

Patients and clinicopathological parameters. Both primary tumor surgery and neck dissection without preoperative treatment underwent in 50 patients with newly diagnosed OSCC with clinical lymph node metastasis at the Aichi Cancer Center Hospital between January 2008 and July 2013, as previously described (2, 9). Among these 50 patients, 28 received pretreatment 18F-FDG-PET/CT at East Nagoya Imaging Diagnosis Center were enrolled in this study. The study was approved by the Institutional Review Board, and informed consent was obtained from each patient prior to
Diagnosis of pN+ and ENE+. The 18F-FDG-uptake parameters of lymph nodes with pN+ and/or ENE+ were reassessed based on a report by Dequanter et al. (7) with minor modifications. Regions of pN+ and/or ENE+ were recorded in reference to the system of the Japan Neck dissection Study Group and classified based on submental and submandibular, jugular, or posterior triangle lymph nodes (5). A site of abnormal accumulation of 18F-FDG on PET/CT was interpreted as the presence of lymph node metastasis, while normal accumulation was considered as metastasis-free. The SUVmax, SUVpeak, MTV, TLG of the lymph node were defined as ln-SUVmax, ln-SUVpeak, ln-MTV, ln-TLG, respectively. For the semiquantitative analysis, the 18F-FDG-uptake parameters of the lymph node of interest, which included ln-SUVmax, ln-SUVpeak, ln-MTV, ln-TLG, were measured from the site of abnormal accumulation. If there were multiple lymph nodes within a certain region, the node with the highest ln-SUVmax was selected. At each region, all PET/CT results were compared with pathological results, which were considered as gold standard.

Statistical analysis. Statistical analyses were performed using JMP software (version 9; SAS Institute: Cary, NC, USA). Simple regression analysis was used to identify correlations between PTV and 18F-FDG-uptake parameters of primary tumor. OS was defined as the duration from FDG-PET/CT to death or last contact and assessed by Kaplan–Meier method. The relationships between OS and the cut-off values for various 18F-FDG-uptake parameters of primary tumor were assessed by Mann-Whitney U- or chi-squared test.

Table I. Clinicopathological parameters of 28 patients with oral squamous cell carcinoma.

| Parameter | Number |
|-----------|--------|
| Age       | Mean±standard deviation (year) 61.1±14.9 |
| Gender    | Male/Female 16/12 |
| Primary tumor site | Tongue/Others 19/9 |
| Type of neck dissection | Unilateral/Bilateral 19/9 |
| Type of postoperative therapy | Chemoradiation/Radiation/Chemotherapy/None 5/4/2/17 |
| Pathological T classification (UICC7th) | T1/T2/T3/T4a/T4b 3/13/7/5/0 |
| Pathological N classification (UICC7th) | N0/N1/N2a/N2b/N2c/N3 7/3/0/17/1/0 |
| Pathological stage (UICC7th) | I/II/III/IVA/IVB 1/4/3/20/0 |
| Positive surgical margin | Presence/Absence 5/23 |
| ENE | ENE+/ENE− 9/19 |
| Positive surgical margin and/or ENE+ | Presence/Absence 12/16 |
| Size | Mean±standard deviation (mm) 33.8±11.7 |
| Tumor thickness | Mean±standard deviation (mm) 16.8±7.4 |
| Depth of invasion | Mean±standard deviation (mm) 14.3±9.3 |
| Pathological tumor volume | Mean±standard deviation (cm³) 8.87±9.06 |
| Lymph node density | Mean±standard deviation 0.06±0.06 |
| Pathological T classification (UICC8th) | T1/T2/T3/T4a/T4b 1/2/20/5/0 |
| Pathological N classification (UICC8th) | N0/N1/N2a/N2b/N2c/N3a/N3b 7/2/1/0/8/3 |
| Pathological stage (UICC8th) | I/II/III/IVA/IVB 0/1/6/13/8 |

OSCC: Oral squamous cell carcinoma; UICC7th: the 7th edition of Union for International Cancer Control; ENE: extranodal extension; UICC8th: the 8th edition of Union for International Cancer Control.
the p-SUVpeak groups in local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS). The area under the curve (AUC) of receiver-operating characteristic curve, sensitivity, 1-specificity were calculated to detect the best cut-off values for \(^{18}\)FDG-uptake parameters of lymph node compare pN\(^+\) versus pathological lymph node metastasis (pN\(-\)), and ENE\(^+\) versus ENE\(-\) by logistic regression analysis. \(p < 0.05\) was considered statistically significant.

Results

**PTV and \(^{18}\)F-FDG-uptake parameters.** Among all patients, the mean\(\pm\)SD values of PTV, p-SUV\(_{\text{max}}\), p-SUVpeak, p-MTV, p-TLG were 8.87\(\pm\)9.06 cm\(^3\), 17.8\(\pm\)6.62 g/ml, 12.1\(\pm\)4.62 g/ml, 5.64\(\pm\)4.70 cm\(^3\), 66.1\(\pm\)61.0 g, respectively. PTV was significantly correlated with both p-MTV \((p<0.01)\) and p-TLG \((p<0.01)\), but not with either p-SUV\(_{\text{max}}\) or p-SUVpeak.

**Clinical course.** The mean\(\pm\)SD duration of follow-up among the whole population, the 18 patients who survived, the 10 patients who died was 45.3\(\pm\)27.0, 62.1\(\pm\)17.0, 15.2\(\pm\)8.23 months, respectively. The 3-year rates of OS, LRFS, RRFS, DMFS, DFS were 64.3\%, 78.3\%, 71.1\%, 76.5\%, 63.8\%, respectively. Pathological stage IVC of UICC8th was significantly correlated with shorter OS than pathological stage I-IVA of UICC8th \((p=0.01)\).

**Cut-off values of \(^{18}\)F-FDG-uptake parameters.** The lowest \(p\) values were p-SUV\(_{\text{max}}\)=19.5 \((p=0.03)\), p-SUVpeak=14.1 \((p<0.01)\), p-MTV=11 \((p=0.049)\), p-TLG=110 \((p=0.049)\). (Figure 1).

**Multivariate OS analysis.** Multivariate analysis adjusted for \(^{18}\)F-FDG-uptake parameters and pathological stage of UICC8th, p-SUVpeak \(\geq\)14.1 \((p=0.047)\) was significantly associated with shorter OS, while p-SUV\(_{\text{max}}\) of \(\geq\)19.5, p-MTV\(\geq\)11, p-TLG\(\geq\)110 were not (Table II).

**The p-SUVpeak groups.** The relations between clinicopathological parameters of the two groups (p-SUV\(_{\text{peak}}\) \(\geq\)14.1; <14.1) are shown in Table III. A p-SUVpeak \(\geq\)14.1 was significantly associated with larger tumor size \((p=0.04)\), greater p-SUV\(_{\text{max}}\) \((p<0.01)\) and p-TLG \((p=0.02)\). A p-SUVpeak \(\geq\)14.1 was significantly associated with shorter LRFS \((p=0.02)\) and DFS \((p<0.01)\). However, there were no significant differences in RRFS or DMFS. The Kaplan–Meier curves are shown in Figure 2.

**pN\(^+\) and ENE\(^+\).** The relations between the \(^{18}\)F-FDG-uptake parameters and pathological findings were assessed in 88 cervical regions. The numbers of regions classified as pN\(^+\) and ENE\(^+\) totaled 31 and 11, respectively. The numbers of regions not classified as pN\(^+\) and ENE\(^+\) totaled 57 and 77.
**Table II. Multivariate analysis of overall survival by a Cox’s proportional hazards model.**

| Characteristic                                                                 | Hazards ratio | 95% confidence interval | p-Value |
|--------------------------------------------------------------------------------|---------------|-------------------------|---------|
| Model 1 Pathological stage (UICC 8th)                                          |               |                         |         |
| p-SUVmax                                                                        | 3.09          | 0.83-12.84              | 0.09    |
| ≥19.5/≤19.5                                                                     | 2.96          | 0.77-14.44              | 0.12    |
| Model 2 Pathological stage (UICC 8th)                                          |               |                         |         |
| p-SUVpeak                                                                       | 4.16          | 1.02-18.88              | 0.047   |
| ≥14.1/≤14.1                                                                     | 3.54          | 0.94-14.63              | 0.06    |
| Model 3 Pathological stage (UICC 8th)                                          |               |                         |         |
| p-MTV                                                                            | 2.29          | 0.47-8.93               | 0.28    |
| ≥11/≤11                                                                         | 3.54          | 0.94-14.63              | 0.06    |
| Model 4 Pathological stage (UICC 8th)                                          |               |                         |         |
| p-TLG                                                                            | 2.29          | 0.47-8.93               | 0.28    |
| ≥110/≤110                                                                        |               |                         |         |

**Table III. Relationships between clinicopathological parameters and p-SUVpeak (<14.1/≥14.1).**

| Parameter                                                                 | p-SUVpeak <14.1 (n=20) | p-SUVpeak ≥14.1 (n=8) | p-Value |
|--------------------------------------------------------------------------|-------------------------|------------------------|---------|
| Age                                                                      | 58.1±15.5               | 68.5±10.6              | 0.13†   |
| Gender                                                                   | 9/11                    | 7/1                    | 0.09*   |
| Primary tumor site                                                      | Tongue/Others           | 14/6                   | 5/3     | 1.00*   |
| Type of neck dissection                                                 | Unilateral/Bilateral    | 13/7                   | 6/2     | 1.00*   |
| Type of postoperative therapy                                           | Presence/Absence         | 7/13                   | 4/4     | 0.67*   |
| Pathological T classification (UICC7th)                                  | T1-T2/T3-T4             | 13/7                   | 3/5     | 0.23*   |
| Pathological N classification (UICC7th)                                  | N0/N1-N2                | 6/14                   | 1/7     | 0.63*   |
| Pathological stage (UICC7th)                                            | I-II/IV                 | 7/13                   | 1/7     | 0.37*   |
| Positive surgical margin                                                | Presence/Absence         | 4/16                   | 1/7     | 1.00*   |
| Extracapsular spread                                                    | Presence/Absence         | 5/15                   | 4/4     | 0.37*   |
| Positive surgical margin or extracapsular spread, or both               | Presence/Absence         | 8/12                   | 4/4     | 0.69*   |
| Lymph node density                                                      | ≥0.06/≤0.06             | 8/12                   | 4/4     | 0.69*   |
| Pathological T classification (UICC8th)                                  | T1-T3/T4a-T4b           | 16/4                   | 7/1     | 1.00*   |
| Pathological N classification (UICC8th)                                  | N0-N1/N2-N3b            | 7/13                   | 2/6     | 1.00*   |
| Pathological stage (UICC8th)                                            | I-II/IVA-IVB            | 6/14                   | 1/7     | 0.63*   |
| Size                                                                     | Mean±S.D.               | 31.0±10.2              | 41.0±12.5 | 0.04†   |
| Depth of invasion                                                       | Mean±S.D.               | 14.4±9.1               | 14.0±10.5 | 0.84†   |
| Tumor thickness                                                         | Mean±S.D.               | 16.4±7.1               | 17.7±8.7 | 0.96†   |
| Pathological tumor volume                                               | Mean±S.D.               | 7658±7743              | 11903±11790 | 0.51†   |
| p-SUVmax                                                                | Mean±S.D.               | 15.0±5.2               | 24.9±4.2 | <0.01†  |
| p-MTV                                                                   | Mean±S.D.               | 4.9±3.9                | 7.6±6.1  | 0.32†   |
| p-TLG                                                                   | Mean±S.D.               | 48.6±45.3              | 109.7±75.8 | 0.02†   |

p-SUVpeak: Peak of standardized uptake value of primary tumor; UICC7th, the 7th edition of Union for International Cancer Control; UICC8th: the 8th edition of Union for International Cancer Control; Control: p-SUVmax: maximum of standardized uptake value of primary tumor; p-MTV: metabolic tumor volume of primary tumor; p-TLG: total lesion glycolysis of primary tumor.

respectively. The best cut-off values to detect pN+ were ln-SUVmax=3.33 (p<0.01, AUC=0.84), ln-SUVpeak=1.82 (p<0.01, AUC=0.82), ln-MTV=0.27 (p=0.43, AUC=0.66), ln-TLG=1.03 (p<0.01, AUC=0.74). The best cut-off values to detect ENE+ were ln-SUVmax=3.61 (p<0.01, AUC=0.80), ln-SUVpeak=1.07 (p<0.01, AUC=0.79), ln-MTV=0.37 (p=0.55, AUC=0.66), ln-TLG=3.1 (p=0.23, AUC=0.74). The highest AUC to detect pN+ and ENE+ were ln-SUVmax=3.33 (sensitivity=80.7%, specificity=77.2%) and ln-SUVmax=3.61 (sensitivity=81.8%, specificity=67.5%), respectively.
The present study showed, for the first time, significant associations between high p-SUVpeak values and lower OS in OSCC by using multivariate analysis adjusted for pathological stage based on UICC8th. Also, high p-SUVpeak was significantly correlated with reduced LRFS and DFS rates.

In head and neck cancer, including OSCC, 18F-FDG-uptake parameters were significantly correlated with OS (3, 4, 10). For example, high p-SUVpeak was predictive of shorter OS in OSCC by multivariate analysis adjusting pathological stage of UICC7th (4). Our findings of a significant association between 18F-FDG-uptake parameters and OS are consistent with these studies (3, 4, 10). Moreover, the present study identified correlations between survival and 18F-FDG uptake parameters in OSCC by multivariate analysis adjusting TNM stage of UICC8th. The present results suggest that pretreatment SUVpeak is a predictor of shorter OS.

The present findings also demonstrated that greater tumor size, p-SUVmax, p-MTV, p-TLG, which were poor predictors of OSCC (4, 13, 14), were significantly correlated with higher p-SUVpeak. Moreover, higher SUVpeak was significantly correlated with worse LRFS and DFS in this study, and we suggest that when SUVpeak is relatively high, more aggressive treatment strategies such as postoperative chemoradiotherapy are needed to improve survival outcomes.

In esophageal cancer, ln-MTV was significantly correlated with pN+ (15). In head and neck cancer, 18F-FDG-uptake was used to evaluate treatment response of lymph node metastasis after chemoradiotherapy (16), and the significant association between 18F-FDG-uptake and chemosensitivity for cisplatin was reported (17). To the best of our knowledge, the usefulness

**Figure 2.** Pathological stage of IVB based on the UICC8th was associated with significantly shorter OS ($p=0.01$), and p-SUVpeak of $\geq 14.1$ was associated with significantly lower OS ($p<0.01$), LRFS ($p=0.02$), DFS ($p<0.01$). UICC8th: The 8th edition of the Union for International Cancer Control, p-SUVpeak: peak standardized uptake value of primary tumor; OS: overall survival; LRFS: local recurrence-free survival; DFS: disease-free survival.
of volumetric 18F-FDG-uptake parameters to predict pN+ and ENE+ has not been investigated. In this study, ln-SUVmax in OSCC had the highest AUC=0.82 to detect both pN+ and ENE+ than ln-MTV, ln-TLG, ln-SUVpeak.

The limitations of the present study include its retrospective design and relatively small number of subjects; thus, prospective analysis with a larger number of subjects is needed to verify these results.

Conclusion

A high p-SUVpeak was correlated with shorter OS in OSCC by multivariate analysis adjusting pathological stage of UICC8th.

Conflicts of Interest

The Authors declare no conflict of interest regarding this study.

Acknowledgements

This study was supported from JSPS KAKENHI Grant Number of 16K11253.

References

1. Brierley J, Gospodarowicz MD and Wittekind C: TNM classification of malignant tumors. International union against cancer. 8th ed. Oxford, England: Wiley-Blackwell; 2016.
2. Suzuki H, Beppu S, Hanai N, Hirakawa H and Hasegawa Y: Lymph node density predicts lung metastasis in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 54: 213-218, 2016.
3. Yabuki K, Sano D, Shiono O, Arai Y, Takahashi H, Chiba Y, Tanabe T, Nishinura G, Takahashi M, Taguchi T, Kaneta T, Hata M and Oridate N: Prognostic significance of metabolic tumor volume in patients with piriform sinus carcinoma treated by radiotherapy with or without concurrent chemotherapy. Head Neck 38: 1666-1671, 2016.
4. Abgral R, Keromnes N, Robin P, Le Roux PY, Bourthois D, Palar X, Rousseau J, Valette G, Marianowski R and Salatun PY: Prognostic value of volumetric parameters measured by 18F-FDG-PET/CT in patients with head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 41: 659-667, 2014.
5. Hasegawa Y and Saikawa M: Update on the classification and nomenclature system for neck dissection: revisions proposed by the Japan Neck Dissection Study Group. Int J Clin Oncol 15: 5-12, 2010.
6. Greenberg JS, Fowler R, Gomez J, Mo V, Roberts D, El Naggar AK and Myers JN: Extent of extracapsular spread: a critical prognosticator in oral tongue cancer. Cancer 97: 1464-70, 2003.
7. Dequanter D, Shahla M, Aubert C, Deniz Y and Lothaire P: Prognostic value of FDG PET/CT in head and neck squamous cell carcinomas. Onco Targets Ther 8: 2279-2283, 2015.
8. Su Z, Duan Z, Pan W, Wu C, Jia Y, Han B and Li C: Predicting extracapsular spread of head and neck cancers using different imaging techniques: a systemic review and meta-analysis. Int J Oral Maxillofac Surg 45: 413-421, 2016.
9. Mukoyama N, Suzuki H, Hanai N, Sone M and Hasegawa Y: Pathological tumor volume predicts survival outcome in oral squamous cell carcinoma. Oncol Lett, 2018. [in press]
10. Suzuki H, Nishio M, Nakanishi H, Hanai N, Hirakawa H, Kodaira T, Tamaki T and Hasegawa Y: Impact of total lesion glycolysis measured by 18F-FDG-PET/CT on overall survival and distant metastasis in hypopharyngeal cancer. Oncol Lett 12: 1493-1500, 2016.
11. Amin BA, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Arai Y, Maderia M, Dogramadze D and Meyer LR: AJCC cancer staging manual, 8th edn. Springer: New York, 2016.
12. Sano D, Yabuki K, Arai Y, Tanabe T, Chiba Y, Nishimura G, Takahashi H, Yamanaka S and Oridate N: The applicability of new TNM classification for human papillomavirus-related oropharyngeal cancer in the 8th edition of the AJCC/UICC TNM staging system in Japan: A single-center study. Auris Nasus Larynx 45: 558-565, 2018.
13. Kim M, Ahmad A, Higuchi T, Ariyaka Y, Yokoo H, Yokoo S and Tsuchiya Y: Effects of intratumoral inflammatory process on 18F-FDG uptake: pathological and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma. J Nucl Med 56: 16-21, 2015.
14. Heiduschka G, Virk SA, Palme CE, Ching S, Eliot M, Gupta R and Clark J: Margin to tumor thickness ratio – A predictor of local recurrence and survival in oral squamous cell carcinoma. Oral Oncol 55: 49-54, 2016.
15. I HS, Kim SJ, Kim SJ and Kim K: Predictive value of metabolic tumor volume measured by 18F-FDG PET for regional lymph node status in patients with esophageal cancer. Clin Nucl Med 37: 442-446, 2012.
16. Nishimura G, Matsuda H, Taguchi T, Takahashi M, Komatsu S, Sano D, Sakuma N, Arai Y and Takahashi H: Treatment evaluation of metastatic lymph nodes after concurrent chemoradiotherapy in patients with head and neck squamous cell carcinoma. Anticancer Res 32: 595-600, 2012.
17. Suzuki H, Nishio M, Hanai N, Hirakawa H, Tamaki T and Hasegawa Y: Correlation between 18F-FDG-uptake and in vitro chemosensitivity of cisplatin in head and neck cancer. Anticancer Res 35: 1009-1016, 2015.

Received April 16, 2018
Revised June 1, 2018
Accepted June 4, 2018